Omid Hariri1,2, Ariel Takayanagi3, Jonathan Lischalk4, Kaniksha Desai5, Timothy J Florence6, Pouria Yazdian7, Steven D Chang1, Frank Vrionis8, John R Adler1, Syed A Quadri9, Atman Desai1. 1. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA. 2. Department of Neurological Surgery, Kaiser Permanente Orange County, Anaheim, CA. 3. Department of Neurosurgery, Riverside University Health Systems, Moreno Valley, CA. 4. Department of Radiation Medicine, Georgetown University, Washington, DC. 5. Department of Medicine-Endocrinology, Gerontology, and Metabolism, Stanford University School of Medicine, Stanford, CA. 6. Columbia College of Physicians and Surgeons, New York, NY. 7. Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Yazd Province, Iran. 8. Department of Neurological Surgery, Marcus Neuroscience Institute, Boca Raton, FL. 9. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
STUDY DESIGN: A retrospective data review. OBJECTIVE: To evaluate the efficacy of CyberKnife (CK) stereotactic radiosurgery (SRS) for thyroid spinal metastasis (SMs). SUMMARY OF BACKGROUND DATA: Thyroid carcinoma is an infrequent cause of SM. The absolute efficacy of SRS generally and CK in particular remains poorly characterized for thyroid SM. The current study is the first to specifically evaluate the efficacy of CK SRS for thyroid SMs. METHODS: A retrospective review of patients at our institution between 2003 and 2013 was done. Details about tumor location, radiographic findings before and after CK SRS, tumor recurrence, prescription isodose level, total and maximum dose, number of fractions, and gross tumor volume coverage were similarly collected. For comparison with other studies, the biologically effective dose and the equivalent total dose in 2 Gy fractions were calculated. Each patient was assessed for survival and local disease control from the time of the first CK session and survival analysis was carried out using the Kaplan-Meier method. Risk factors for local failure were assessed using multivariate logistic regression. RESULTS: A total of 12 patients with 32 spinal metastases from thyroid carcinoma that were treated with CK SRS were identified. Survival for 1, 2, and 3 years was 55%, 44%, and 33%, and local control was 67%, 56%, and 34% respectively. The study found that the single strongest factor associated with local control was prior radiotherapy (β-coefficient -27.72, P = 0.01). No complications occurred in the immediate or late follow-up period. CONCLUSION: This was the first study to specifically investigate the efficacy of CK for treatment of thyroid SMs. Our findings suggest that CK can be safely used to treat spinal SMs from thyroid cancer and is associated with a high rate of local control. LEVEL OF EVIDENCE: 4.
STUDY DESIGN: A retrospective data review. OBJECTIVE: To evaluate the efficacy of CyberKnife (CK) stereotactic radiosurgery (SRS) for thyroid spinal metastasis (SMs). SUMMARY OF BACKGROUND DATA: Thyroid carcinoma is an infrequent cause of SM. The absolute efficacy of SRS generally and CK in particular remains poorly characterized for thyroid SM. The current study is the first to specifically evaluate the efficacy of CK SRS for thyroid SMs. METHODS: A retrospective review of patients at our institution between 2003 and 2013 was done. Details about tumor location, radiographic findings before and after CK SRS, tumor recurrence, prescription isodose level, total and maximum dose, number of fractions, and gross tumor volume coverage were similarly collected. For comparison with other studies, the biologically effective dose and the equivalent total dose in 2 Gy fractions were calculated. Each patient was assessed for survival and local disease control from the time of the first CK session and survival analysis was carried out using the Kaplan-Meier method. Risk factors for local failure were assessed using multivariate logistic regression. RESULTS: A total of 12 patients with 32 spinal metastases from thyroid carcinoma that were treated with CK SRS were identified. Survival for 1, 2, and 3 years was 55%, 44%, and 33%, and local control was 67%, 56%, and 34% respectively. The study found that the single strongest factor associated with local control was prior radiotherapy (β-coefficient -27.72, P = 0.01). No complications occurred in the immediate or late follow-up period. CONCLUSION: This was the first study to specifically investigate the efficacy of CK for treatment of thyroid SMs. Our findings suggest that CK can be safely used to treat spinal SMs from thyroid cancer and is associated with a high rate of local control. LEVEL OF EVIDENCE: 4.
Authors: A Nervo; A Ragni; F Retta; M Gallo; A Piovesan; V Liberini; M Gatti; U Ricardi; D Deandreis; E Arvat Journal: J Endocrinol Invest Date: 2020-08-03 Impact factor: 4.256